{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:59:45Z","timestamp":1785196785020,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.japh.2026.103139","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:33:47Z","timestamp":1778859227000},"page":"103139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sulfamethoxazole-trimethoprim-induced Stevens-Johnson syndrome in a NAT2 slow acetylator: A case for pre-emptive pharmacogenomic screening?"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-3316","authenticated-orcid":false,"given":"Siok Ying","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Kok Choon","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2026.103139_bib1","first-page":"1","article-title":"Health Sciences Authority Adverse Drug Reaction News","volume":"27","year":"2025"},{"key":"10.1016\/j.japh.2026.103139_bib2","first-page":"1","year":"2022","journal-title":"DBL Sulfamethoxazole-Trimethoprim"},{"issue":"5","key":"10.1016\/j.japh.2026.103139_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamadermatol.2024.0210","article-title":"Human leukocyte antigens and sulfamethoxazole\/cotrimoxazole-induced severe cutaneous adverse reactions: A systematic review and meta-analysis","volume":"160","author":"Wu","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.japh.2026.103139_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2156-9-21","article-title":"Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history","volume":"9","author":"Sabbagh","year":"2008","journal-title":"BMC Genet"},{"issue":"7","key":"10.1016\/j.japh.2026.103139_bib5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bcp.2008.07.024","article-title":"Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers","volume":"76","author":"Muscat","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2026.103139_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/jpm11020071","article-title":"Pharmacogenomics of allopurinol and sulfamethoxazole\/trimethoprim: case series and review of the literature","volume":"11","author":"Ikediobi","year":"2021","journal-title":"J Pers Med"},{"issue":"8","key":"10.1016\/j.japh.2026.103139_bib7","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3390\/ijms26083881","article-title":"NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort","volume":"26","author":"Schiuma","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.japh.2026.103139_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186200","article-title":"Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients","volume":"12","author":"Chan","year":"2017","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.japh.2026.103139_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/jhg.2016.10","article-title":"NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis","volume":"61","author":"Yuliwulandari","year":"2016","journal-title":"J Hum Genet"},{"issue":"18","key":"10.1016\/j.japh.2026.103139_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/pgs-2019-0131","article-title":"NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population","volume":"20","author":"Yuliwulandari","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.japh.2026.103139_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2013.229","article-title":"Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing","volume":"95","author":"Van Driest","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.japh.2026.103139_bib12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive pharmacogenomic testing for Precision medicine","volume":"18","author":"Ji","year":"2016","journal-title":"J Mol Diagn"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912600124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431912600124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:31:04Z","timestamp":1785195064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431912600124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S154431912600124X"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103139","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfamethoxazole-trimethoprim-induced Stevens-Johnson syndrome in a NAT2 slow acetylator: A case for pre-emptive pharmacogenomic screening?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103139"}}